These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21570356)

  • 1. The HVTN 503/Phambili study: efficacy is always the issue.
    Dhesi Z; Stebbing J
    Lancet Infect Dis; 2011 Jul; 11(7):490-1. PubMed ID: 21570356
    [No Abstract]   [Full Text] [Related]  

  • 2. Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.
    Moodie Z; Metch B; Bekker LG; Churchyard G; Nchabeleng M; Mlisana K; Laher F; Roux S; Mngadi K; Innes C; Mathebula M; Allen M; Bentley C; Gilbert PB; Robertson M; Kublin J; Corey L; Gray GE
    PLoS One; 2015; 10(9):e0137666. PubMed ID: 26368824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials.
    Zolla-Pazner S; Michael NL; Kim JH
    Lancet HIV; 2021 Jul; 8(7):e449-e452. PubMed ID: 34029515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A relative standard for minimal risk is unnecessary and potentially harmful to children: lessons from the Phambili trial.
    Nelson RM
    Am J Bioeth; 2011 Jun; 11(6):14-6. PubMed ID: 21678206
    [No Abstract]   [Full Text] [Related]  

  • 5. South African AIDS Vaccine Initiative launches phase I trial.
    Kresge KJ
    IAVI Rep; 2009; 13(4):19. PubMed ID: 20225578
    [No Abstract]   [Full Text] [Related]  

  • 6. Don't stop me now.
    Nat Immunol; 2008 Aug; 9(8):821. PubMed ID: 18645584
    [No Abstract]   [Full Text] [Related]  

  • 7. Why we don't need a relative risk standard for adolescent HIV vaccine trials in South Africa.
    Slack CM
    Am J Bioeth; 2011 Jun; 11(6):21-2. PubMed ID: 21678209
    [No Abstract]   [Full Text] [Related]  

  • 8. AIDS vaccine test to be expanded based on upbeat results.
    AIDS Read; 2005 Nov; 15(11):561, 573. PubMed ID: 16329176
    [No Abstract]   [Full Text] [Related]  

  • 9. Willingness to participate in biomedical HIV prevention studies after the HVTN 503/Phambili trial: a survey conducted among adolescents in Soweto, South Africa.
    Otwombe KN; Sikkema KJ; Dietrich J; de Bruyn G; van der Watt M; Gray GE
    J Acquir Immune Defic Syndr; 2011 Oct; 58(2):211-8. PubMed ID: 21765362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (Un)risky business: adolescents and HIV prevention trials.
    Philpott S
    Am J Bioeth; 2011 Jun; 11(6):17-9. PubMed ID: 21678207
    [No Abstract]   [Full Text] [Related]  

  • 11. Support for the RV144 HIV vaccine trial.
    Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
    [No Abstract]   [Full Text] [Related]  

  • 12. [Development of a vaccine against HIV: is this aim accomplishable?].
    Wagner R; Asbach B
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():36-9. PubMed ID: 23961653
    [No Abstract]   [Full Text] [Related]  

  • 13. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outstanding questions on HIV vaccine trial.
    Jefferys R; Harrington M
    Science; 2004 Jul; 305(5681):180; author reply 180. PubMed ID: 15247456
    [No Abstract]   [Full Text] [Related]  

  • 15. Is the current use of 'positivity' thresholds meaningful for evaluating HIV-vaccine immunogenicity endpoints?
    Richert L; Thiebaut R;
    AIDS; 2013 May; 27(8):1362-5. PubMed ID: 23759712
    [No Abstract]   [Full Text] [Related]  

  • 16. Mucosally-targeted HIV-1 vaccines.
    Wegmann F
    Hum Vaccin; 2011 Sep; 7(9):982-5. PubMed ID: 21892008
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV-1 T-cell vaccines: evaluating the next step.
    Pantaleo G
    Lancet Infect Dis; 2008 Feb; 8(2):82-3. PubMed ID: 18060842
    [No Abstract]   [Full Text] [Related]  

  • 18. The potential role of the HIV-1 immunogen (Remune) as a therapeutic vaccine in the treatment of HIV infection.
    Fernández-Cruz E; Navarro J; Rodríguez-Sainz C; Gil J; Moreno S; González-Lahoz J; Carbone J
    Expert Rev Vaccines; 2003 Dec; 2(6):739-52. PubMed ID: 14711358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prospects for vaccine development against HIV infection].
    Kurth R; Binninger D; Ennen J; Denner J; Hartung S; Norley S
    Verh Dtsch Ges Inn Med; 1991; 97():394-402. PubMed ID: 1808921
    [No Abstract]   [Full Text] [Related]  

  • 20. Delaying the immune-suppressive function of regulatory T cells might enhance immune responses against HIV vaccines.
    Immunotherapy; 2010 May; 2(3):301. PubMed ID: 20658753
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.